Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer
This study is currently recruiting participants.
Verified by Alberta Cancer Board, April 2007
Sponsored by: Alberta Cancer Board
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00124423
  Purpose

The Cross Cancer Institute has recently acquired a tomotherapy radiotherapy treatment machine; the first of its kind in Canada. It has the potential to improve cancer treatment outcomes where radiotherapy is used. Cervix cancer is a disease where radiotherapy is a particularly important treatment modality. The researchers believe that by combining tomotherapy (which has the ability to give higher doses of radiation to areas of cancer while sparing normal tissues) with radiotherapy given from inside the uterus and vagina (brachytherapy) disease outcomes will be improved. For this to be possible the researchers will need to accurately map the doses of radiation given to the cervix, uterus and other pelvic organs from these two types of radiation treatment. As well as being used for treatment, the tomotherapy machine can also be used for taking medical images by using very much lower doses of radiation. This study will allow the researchers to develop the mapping process by using very low doses of radiation on the tomotherapy unit to take medical x-ray images of patients being treated by brachytherapy for cervix cancer. In this special circumstance the researchers expect the images to be of a higher quality than for conventional computed tomography (CT) scanning or magnetic resonance imaging (MRI) scanning.


Condition Intervention
Cervix Cancer
Procedure: Megavoltage CT scan

MedlinePlus related topics: CT Scans Cancer Cervical Cancer Nuclear Scans
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer

Further study details as provided by Alberta Cancer Board:

Estimated Enrollment: 5
Study Start Date: June 2004
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing brachytherapy for cervix cancer

Exclusion Criteria:

  • Patient refusal
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00124423

Contacts
Contact: Robert Pearcey, MD 780-432-8749 robertpe@cancerboard.ab.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Clinical Research Unit     780-989-8152     clinical_trials_cci@cancerboard.ab.ca    
Principal Investigator: Robert Pearcey, MD            
Sponsors and Collaborators
Alberta Cancer Board
Investigators
Principal Investigator: Robert Pearcey, MD Alberta Cancer Board
  More Information

Study ID Numbers: GY-03-0018
Study First Received: July 26, 2005
Last Updated: September 22, 2008
ClinicalTrials.gov Identifier: NCT00124423  
Health Authority: Canada: Health Canada

Keywords provided by Alberta Cancer Board:
brachytherapy megavoltage CT imaging

Study placed in the following topic categories:
Genital Diseases, Female
Uterine Cervical Neoplasms
Uterine Cervical Diseases
Genital Neoplasms, Female
Uterine Diseases
Uterine Neoplasms
Urogenital Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009